ANDROMEDA, A raNdomized, Double-blind, double-dummy, multicentre, phase IIIb, parallel-group study to compare the efficacy and safety of Rosuvastatin (10 mg and 20 mg) and atOrvastatin (10 Mg and 20 mg) in patiEnts with type 2 DiAbetes mellitus.
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes
Article first published online: 15 MAR 2007
Volume 24, Issue 5, pages 541–549, May 2007
How to Cite
Betteridge, D. J. and Gibson, J. M. (2007), Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic Medicine, 24: 541–549. doi: 10.1111/j.1464-5491.2007.02095.x
Published as an abstract (< 300 words) for the 75th European Atherosclerosis Society Congress, 2005. Citation: Betteridge DJ, Gibson JM, Sager P. Effect of rosuvastatin and atorvastatin on CRP levels in patients with type 2 diabetes: results from the ANDROMEDA study. Atherosclerosis Suppl 2005; 6: 102 (Abstract W16-P-007).
Also published as an abstract (< 300 words) for the 64th Scientific Sessions of the American Diabetes Association, 2004. Citation: Betteridge DJ, Gibson M. Effects of rosuvastatin and atorvastatin on non-HDL-C levels in patients with type 2 diabetes: results of the ANDROMEDA study. Diabetes 2004; 53 (Suppl. 2): A227 (Abstract 927-P).
- Issue published online: 22 MAR 2007
- Article first published online: 15 MAR 2007
- Accepted 4 November 2006
- low-density lipoprotein cholesterol;
- Type 2 diabetes
Aims To compare the effects of rosuvastatin and atorvastatin 10 and 20 mg on plasma lipid and lipoprotein profiles in patients with Type 2 diabetes mellitus and triglycerides ≤ 6.0 mmol/l.
Methods A double-blind, randomized, multicentre study to assess the effect of rosuvastatin and atorvastatin, at 10 mg/day for 8 weeks followed by 20 mg/day for a further 8 weeks, on low-density lipoprotein cholesterol (LDL-C), together with a range of secondary lipid and lipoprotein end points.
Results Rosuvastatin reduced mean LDL-C levels from baseline over 16 weeks by 57.4%, while atorvastatin reduced mean LDL-C levels by 46.0% over the same period. The difference in LDL-C reduction between treatments was statistically significant (P < 0.001). Rosuvastatin also produced statistically significantly greater mean reductions from baseline in levels of total cholesterol, non-high-density lipoprotein cholesterol, apolipoprotein B and lipid ratios. More patients achieved European LDL-C (< 2.5 mmol/l) and total cholesterol (< 4.5 mmol/l) goals with rosuvastatin than with atorvastatin. Rosuvastatin was associated with a significantly (P < 0.049) greater mean percentage increase in glycated haemoglobin (HbA1c) from baseline compared with atorvastatin; however, patients in both treatment groups maintained good glycaemic control. Both rosuvastatin and atorvastatin were well tolerated.
Conclusions Greater reductions in LDL-C were achieved with rosuvastatin compared with equal doses of atorvastatin, enabling more patients with Type 2 diabetes to achieve European LDL-C goals.